Literature DB >> 2830334

Evolution of B cell lineage lymphomas in mice with a retrovirus-induced immunodeficiency syndrome, MAIDS.

S P Klinken1, T N Fredrickson, J W Hartley, R A Yetter, H C Morse.   

Abstract

Mice infected with LP-BM5 murine leukemia virus develop lymphadenopathy, splenomegaly, hypergammaglobulinemia, and profound immunosuppression associated with enhanced susceptibility to infection. In this study, molecular genetic analyses of spleen and lymph node cells from infected mice showed the early course of disease was associated with polyclonal proliferations of both B and T cells but that by 12 wk oligoclonal expansions of B or T cells could be detected. When near death, the mice were killed and almost all exhibited clonally restricted populations of B cells, and continuous cultures of B lineage cells were established from three of 19 mice. Histologically, lymph nodes with polyclonal lymphoproliferative lesions were indistinguishable from nodes with clonally restricted populations of cells. However, aggressive immunoblastic lymphomas of characteristic morphology were seen in nonlymphoid organs, particularly in the brain. The demonstration of terminal B cell lymphomas in murine AIDS extends the similarities between this syndrome and AIDS in humans.

Entities:  

Mesh:

Year:  1988        PMID: 2830334

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Susceptibility to a mouse acquired immunodeficiency syndrome is influenced by the H-2.

Authors:  D Hamelin-Bourassa; E Skamene; F Gervais
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

2.  Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?

Authors:  Wen Li; William R Green
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

3.  Effects of non-MHC loci on resistance to retrovirus-induced immunodeficiency in mice.

Authors:  M Makino; W F Davidson; T N Fredrickson; J W Hartley; H C Morse
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

4.  Characteristics and contributions of defective, ecotropic, and mink cell focus-inducing viruses involved in a retrovirus-induced immunodeficiency syndrome of mice.

Authors:  S K Chattopadhyay; D N Sengupta; T N Fredrickson; H C Morse; J W Hartley
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

5.  Myeloid-derived suppressor cells in murine AIDS inhibit B-cell responses in part via soluble mediators including reactive oxygen and nitrogen species, and TGF-β.

Authors:  Jessica L Rastad; William R Green
Journal:  Virology       Date:  2016-09-12       Impact factor: 3.616

6.  Recovery from retrovirus-induced immune suppression in BDP/J mice: dominance of the "regressor' phenotype.

Authors:  G L Gilmore
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

7.  Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency.

Authors:  Kathy A Green; W James Cook; William R Green
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Murine AIDS is initiated in the lymph nodes draining the site of inoculation, and the infected B cells influence T cells located at distance, in noninfected organs.

Authors:  C Simard; M Huang; P Jolicoeur
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.

Authors:  K A Green; K M Crassi; J D Laman; A Schoneveld; R R Strawbridge; T M Foy; R J Noelle; W R Green
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Adoptive transfer of polyclonal and cloned cytolytic T lymphocytes (CTL) specific for mouse AIDS-associated tumors is effective in preserving CTL responses: a measure of protection against LP-BM5 retrovirus-induced immunodeficiency.

Authors:  W R Green; K A Green; K M Crassi
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.